Primary liver tumors: Origin and target therapy

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 8, 2009, Pages 957-965

  Papoulas, Michail ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cancer; Liver; Stem cells; Treatment

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ATAXIN 1; CD34 ANTIGEN; CD45 ANTIGEN; CELL MARKER; CHROMOGRANIN A; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 7; CYTOKERATIN 8; FLT3 LIGAND; IMATINIB; INTERLEUKIN 12; NERVE CELL ADHESION MOLECULE; PARATHYROID HORMONE RELATED PROTEIN; STEM CELL DIFFERENTIATION STAGE FACTOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CELL HYPERPLASIA; CELL REGENERATION; CELL THERAPY; CHEMOEMBOLIZATION; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; GENE THERAPY; HEPATOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LIVER CELL; LIVER CELL CARCINOMA; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; CHOLANGIOCARCINOMA; DRUG DELIVERY SYSTEMS; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 69149084667     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220903074588     Document Type: Review

References (84)

1. Michalopoulos GK, DeFrances MC. Liver Regeneration. Science 1997;276:60-636
2. Fausto N, Campbell JS, Riehle KJ. Liver Regeneration. Hepatology 2006;43:S45-53
3. Michalopoulos GK. Liver Regeneration. J Cell Physiol 2007;213:286-300
4. Liovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917
5. Roskams T. Different types of liver progenitor cells and their niches. J Hepatol 2006;45:1-4 • An important paper presenting the ancestors of hepatocytes, their role as well as markers for their characterization. (Pubitemid 43850628)
6. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002;347:1593-1603
7. Wu X-Z, Yu X-H. Bone marrow cells: the source of hepatocellular carcinoma? Med Hypotheses 2007;69:36-42
8. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells and stem cells. Hepatology 2004;39:1477-1487 (Pubitemid 38702646)
9. Kim L, Park YN, Kim SE, et al. Teratoid hepatoblastoma: multidirectional differentiation of stem cell of the liver. Yonsei Med J 2001;42:431-435
10. Ruck P, Xiao JC. Stem-like cells in hepatoblastoma. Med Pediatr Oncol 2002;39:504-507
11. Fiegel HC, Glüer S, Roth B, et al. Stem-like cells in human hepatoblastoma. J Histochem Cytochem 2004;52:1495-1501
12. Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma: the role of oral contraceptive use. JAMA 1979;242:644-648
13. Libbrecht L, De Vos R, Cassiman D, et al. Hepatic progenitor cells in hepatocellular adenomas. Am J Surg Pathol 2001;25:1388-1396 (Pubitemid 33022054)
14. Sell S. Cellular origin of cancer: dedifferentiation or stem cell maturation arrest? Environ Health Perspect 1993;101(Suppl 5):15-26
15. Kim H, Park C, Han KH, et al. Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 2004;40:298-304 (Pubitemid 38115836)
16. Lee JH, Rim HJ, Sell S. Heterogeneity of the "oval-cell" response in the hamster liver during cholangiocarcinogenesis following Clonorchis sinensis infection and dimethylnitrosamine treatment. J Hepatol 1997;26:1313-1323
17. Steinberg P, Steinbrecher R, Radaeva S, et al. Oval cell lines OC/CDE 6 and OC/CDE 22 give rise to cholangiocellular and undifferentiated carcinomas after transformation. Lab Invest 1994;71:700-709 (Pubitemid 24374577)
18. Asayama Y, Aishima S, Taguchi K, et al. Coexpression of neural cell adhesion molecules and bcl-2 in intrahepatic cholangiocarcinoma originated from viral hepatitis: relationship to atypical reactive bile ductule. Pathol Int 2002;52:300-306 (Pubitemid 34587816)
19. Roskams T, van den Oord JJ, De Vos R, Desmet VJ. Neuroendocrine features of reactive bile ductules in cholestatic liver disease. Am J Pathol 1990;137:1019-1025
20. Fabris L, Strazzabosco M, Crosby HA, et al. Characterization and isolation of ductular cells coexpressing neural cell adhesion molecule and Bcl-2 from primary cholangiopathies and ductal plate malformations. Am J Pathol 2000;156:1599-1612 (Pubitemid 30646699)
21. Haas S, Gütgemann I, Wolff M, Fischer HP. Intrahepatic clear cell cholangiocarcinoma: immunohistochemical aspects in a very rare type of cholangiocarcinoma. Am J Surg Pathol 2007;31:902-906 (Pubitemid 47165144)
22. Ishikawa K, Sasaki A, Haraguchi N, et al. A case of an α-fetoprotein-producing intrahepatic cholangiocarcinoma suggests probable cancer stem cell origin. Oncologist 2007;12:320-324 (Pubitemid 46556798)
23. Liu C, Wang J, Ou QJ. Possible stem cell origin of human cholangiocarcinoma. World J Gastroenterol 2004;10:3374-3376 (Pubitemid 39585486)
24. Wu X-Z, Chen D. Origin of hepatocellular carcinoma: role of stem cells. J Gastroenterol Hepatol 2006;21:1093-1098 • This review article elucidates the cellular origin of HCC and the role of stem cells. (Pubitemid 43909997)
25. Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556 • An important paper describing identification of a CSCs population in HCC. (Pubitemid 46890873)
26. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-648 (Pubitemid 24067706)
27. Bonnet D, Dick JE. Human acute myeloid leukaemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737 (Pubitemid 27298715)
28. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-5511 (Pubitemid 40911148)
29. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121:823-835 (Pubitemid 40806415)
30. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110 (Pubitemid 46067310)
31. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115 (Pubitemid 46067311)
32. + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-1708
33. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006;44:240-251 (Pubitemid 44049156)
34. Libbrecht L, Roskams T. Hepatic progenitor cells in human liver disease. Semin Cell Dev Biol 2002;13:389-396 (Pubitemid 36027142)
35. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006;49(2):138-151
36. Dumble ML, Croager EJ, Yeoh GC, Quail EA. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis 2002;23:435-445
37. Braun L, Mikumo R, Fausto N. Production of hepatocellular carcinoma by oval cells: cell cycle expression of c-myc and p53 at different stages of oval cell transformation. Cancer Res 1989;49:1554-1561 (Pubitemid 19088697)
38. Tsao M-S, Grisham JW. Hepatocarcinomas, cholangiocarcinomas and hepatoblastomas produced by chemically transformed cultured rat liver epithelial cells: a light and electron microscopic analysis. Am J Pathol 1987;127:168-181
39. Sell S. Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol 2002;13:419-424
40. Tang Y, Kitisin K, Jogunoori W, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling. Proc Natl Acad Sci USA 2008;19(105):2445-2450
41. Massagué J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000;13(103):295-309
42. Mishra L, Derynck R, Mishra B. TGF-β signaling pathway in stem cells. Science 2005;310:68-71
43. Kanzler S, Meyer E, Lohse AW, et al. Hepatocellular expression of a dominant-negative mutant TGF-β type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene 2001;20:5015-5024 (Pubitemid 32769791)
44. Naiche LA, Harrelson Z, Kelly RG, Papaioannou VE. T-box genes in vertebrate development. Annu Rev Genet 2005;39:219-239
45. Suzuki A, Sekiya S, Büscher D, et al. Tbx3 controls the fate of hepatic progenitor cells in liver development by suppressing p19ARF expression. Development 2008;135:1589-1595 (Pubitemid 351895488)
46. Koch A, Denkhaus D, Albrecht S, et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res 1999;59:269-273 (Pubitemid 29048850)
47. Chen YW, Jeng YM, Yeh SH, Chen PJ. p53 gene and Wnt signaling in benign neoplasms: β-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002;36:927-935
48. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847-8851 (Pubitemid 28350577)
49. Sugimachi K, Taguchi K, Aishima S, et al. Altered expression of β-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 2001;14:900-905 (Pubitemid 32889249)
50. Rashid A. Cellular and molecular biology of biliary tract cancers. Surg Oncol Clin North Am 2002;11:995-1009 (Pubitemid 35397235)
51. Thompson MD, Monga SP. WNT/β-catenin signaling in liver health and disease. Hepatology 2007;45:1298-1305 (Pubitemid 46775794)
52. Roura S, Miravet S, Piedra J, et al. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem 1999;274:36734-36740 (Pubitemid 30005291)
53. Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res 2002;62:2064-2071 (Pubitemid 34408453)
54. Wu PC, Fang JW, Lau VK, et al. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol 1996;149:1167-1175
55. Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003;94:851-857 (Pubitemid 37406966)
56. Morinaga S, Ishiwa N, Noguchi Y, et al. Growth index, assessed with Ki-67 and ssDNA labeling; a significant prognosticator for patients undergoing curative resection for hepatocellular carcinoma. J Surg Oncol 2005;92:331-336 (Pubitemid 41779292)
57. Ho JW, Pang RW, Lau C, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006;44:836-843 (Pubitemid 46489546)
58. Yu D, Sun X, Qiu Y, et al. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin Cancer Res 2007;13:3814-3824 (Pubitemid 47037586)
59. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-IA antigen (Ep-CAM). J Mol Med 1999;77:699-712
60. Kim JW, Ye Q, Forgues M, et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004;39:518-527 (Pubitemid 38222194)
61. Yamashita T, Forgues M, Wang W, et al. EpCAM and α-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-1461 (Pubitemid 351346853)
62. + cancer stem cells in human liver cancer. Cancer Cell 2008;13:153-166
63. Cha C, DeMatteo RP, Blumgart LH. Surgery and ablative therapy for hepatocellular carcinoma. J Clin Gastroenterol 2002;35:S130-7 (Pubitemid 35278650)
64. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004;127:S218-24
65. Trinchet JC, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 1997;27:756-765 (Pubitemid 27448761)
66. Theise ND, Yao JL, Harada K, et al. Hepatic 'stem cell' malignancies in adult: four cases. Histopathology 2003;43:263-271
67. Di Maio M, De Maio E, Perrone F, et al. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol 2002;35:S109-14
68. Farmer DG, Seu P, Swenson K, et al. Current and future treatment modalities for hepatocellular carcinoma. Clin. Liver Dis 1997;1:361-396
69. Zhong XG, He S, Yin W, et al. Tropism of adult liver stem cells toward hepatocellular carcinoma cells in vitro. Zhonghua Ganzangbing Zazhi 2005;13:644-647
70. Zhong XG, He S, Yin W, et al. Selective tropism of liver stem cells to hepatocellular carcinoma in vivo. World J Gastroenterol 2007;13:3886-91 • This important paper investigated in vivo the selective tropism of liver stem cells to HCC. (Pubitemid 47272319)
71. Song S, Witek RP, Lu Y, et al. Ex vivo transduced liver progenitor cells as a platform for gene therapy in mice. Hepatology 2004;40:918-924 (Pubitemid 39288125)
72. Shurin MR, Esche C, Péron JM, Lotze MT. Antitumor activities of IL-12 and mechanisms of action. Chem Immunol 1997;68:153-174 (Pubitemid 27420364)
73. Peron JM, Couderc B, Rochaix P, et al. Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12. J Gastroenerol Hepatol 2004;19:388-96 • An important paper describing a new treatment approach-experimental HCC can be efficiently and safely treated using ex vivo IL-12 gene therapy. (Pubitemid 38570188)
74. Thorgeirsson SS. Progenitor cell tumors in human liver. Liver 1998;18:227-228
75. Fujio K, Hu Z, Evarts RP, et al. Coexpression of stem cell factor and c-kit in embryonic and adult liver. Exp Cell Res 1996;224:243-250 (Pubitemid 26140558)
76. Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001;25:571-576 (Pubitemid 32506764)
77. DeSilva CM, Reid R. Gastrointestinal stromal tumors (GIST): c-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 2003;9:13-19 (Pubitemid 36604534)
78. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056 (Pubitemid 32267975)
79. Ramadori G, Fυzesi L, Grabbe E, et al. Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anti Cancer Drugs 2004;15:405-409 (Pubitemid 38526766)
80. Becker G, Schmitt-Graeff A, Ertelt V, et al. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol 2007;19:204-208 (Pubitemid 46268578)
81. Chiba T, Zheng YW, Kita K, et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 2007;133:937-950 • An important paper indicating the role of HSCs-HPCs in the hepatocarcinogenesis through their dysregulated self-renewal and highlighting the role of important signaling pathways. (Pubitemid 47374130)
82. Livraghi T, Meloni F, Frosi A, et al. Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: an open randomized clinical trial. Oncol Res 2005;15:399-408 (Pubitemid 43198597)
83. Alison MR, Lovell MJ. Liver cancer: the role of stem cells. Cell Prolif 2005;38:407-421 (Pubitemid 41746372)
84. + bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 2005;23:463-470